STEKOTCWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Stemtech Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $207.74K
- P/E (TTM)
- –
- Dividend yield
- –
Stemtech Corp revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Latin America [Member] | $1.53M | $2.67M | $3.07M | $2.50M | $1.67M | 53.2% | -42.7% |
| Americas [Member] | $1.23M | $2.17M | $1.68M | $1.55M | $1.87M | 42.8% | -43.3% |
| Asia [Member] | $116.91K | $215.26K | $180.27K | $510.93K | $786.84K | 4.1% | -45.7% |
From the segment and revenue-disaggregation notes of Stemtech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.